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The Jefferson Center For Diabetic 
Kidney Disease 
End-stage renal disease from diabetes carries with it a risk of death that few people 
appreciate. Patients with this disease carry greater risk of death within five years 
than patients with newly diagnosed HIV or newly diagnosed breast cancer. Diabetic 
nephropathy has increased enormously and now accounts for over 40% of all new 
cases of endstage renal failure in the United States.1 Over the past 20 years, 
diabetic nephropathy has increased over ten-fold in incidence in the state of 
Pennsylvania.1
What are the factors underlying this alarming trend? With the knowledge gained 
from studies showing the benefits of ACE inhibitors in reducing proteinuria and 
retarding progressive renal disease2, it was assumed that diabetic nephropathy 
would soon be another victim of medical success. This has not proved to be the case 
for several reasons: 1) the pool of patients with the potential to develop nephropathy 
has increased due to both better medical care and to the increasing number of obese 
adult-onset diabetic patients, and 2) ACE inhibitors can decrease the rate of 
progression, but only if the patients attain optimal blood pressure control. 
 
Based on two large clinical trials, the target blood pressure for the diabetic patient 
with proteinuria should be less than 150/85 mm Hg and ideally at 125/75 mm Hg 3,4.
The challenge of caring for the diabetic patient with evidence of kidney disease is to 
protect those remaining delicate nephrons from being exposed to ongoing high blood 
pressures and elevated blood sugars. Careful attention to these basic issues can 
mean the difference between prolonged preservation of adequate renal function and 
the need for renal replacement therapy.  Delivering optimal care to these patients 
remains an ongoing challenge to the physician. At Jefferson, we have formed a 
Center for Diabetic Kidney Disease (CDKD) to increase both public awareness of 
diabetic nephropathy and to educate physicians about the importance of aggressive 
intervention. The CDKD at Jefferson integrates the resources of clinicians and 
researchers from the divisions of Nephrology and Endocrinology to provide intensive 
management of the patient with established diabetic nephropathy.  Patients benefit 
from receiving care in one team-oriented setting with nephrologists, 
endocrinologists, and dieticians working closely together and in coordination with the 
primary care physician. The CDKD has evaluated and managed more than 300 
patients since its inauguration in 1996. 
 
Current clinical research studies at the CDKD are focused on determining optimal 
blood pressure lowering agents, evaluating new anti-fibrotic agents that may prevent 
progression of nephropathy, and identifying DNA polymorphisms and other markers 
that may predict the incidence and progression of nephropathy. To schedule an 
appointment or for more information about the Jefferson Center for Diabetic Kidney 
Disease, please call 215-503-6950. 
 
(Members of the Center for Diabetic Kidney Disease include Serge Jabor, 
endocrinologist; Tracy McGowan, nephrologist and clinical research investigator; 
Barbara Whedon, nutritionist; Barbara Francos, clinical research coordinator; and 
Dana Wames, administrator.) 
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